Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Videos|October 1, 2025

Behind the Headlines Episode 26: Clinical Advances, Weight-Loss Deals, and Swiss Startup Strength

Author(s)Chris Spivey

Pfizer re-balances weight loss portfolio with Metsera, Bristol Myers Squibb and Roche make breast cancer progress, and Keytruda gets under your skin.

Behind the Headlines bi-weekly episodes examine the ongoing trends, factors and fashions that cause pharmaceutical news to happen. Panelists are a mix of consultants, venture capitalists, scientists, patient advocates, journalists and editors. Each episode talks about the current headlines of the preceding weeks that are on everyone’s lips but seeks to highlight the more enduring lessons that hide behind these headlines.

In Episode 26, Sirpa Tsimal, Global Marketing Director, Switzerland Global Enterprise; Philip Just Larsen, MD, PhD, CEO, Six Peaks Bio; and Stephan Emmerth, Director of Business Development & Operations, BaseLaunch, take a close look at recent clinical trial progress, including Bristol Myers Squibb’s successful phase 3 results for relapsed refractory multiple myeloma (1) and Roche’s evERA study on advanced breast cancer (2), alongside Eli Lilly and Company's oral treatment for ESR1-mutated breast cancer (3) and Merck 's FDA approval for subcutaneous keytruda delivery (4).

Because of its very clear importance to Scandinavian countries, this all Swiss-based panel also examined the reasons behind Pfizer’s Metsera acquisition for $4.9Billion (5), a key move to re-shape the weight loss drug landscape, once again.

The panel also discussed what makes for a great set of accelerator business conditions for life sciences and scores Switzerland’s performance for several of the most important factors determining successful outcomes for the life science industry, most especially as they relate to innovative young companies, as well as the university systems that feed them, alongside the big pharma companies that help sustain the momentum being built.

References

  1. Bristol Myers Squibb. Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma. Press Release. Sept 23, 2025.
  2. Roche. Positive Phase III Results Show Roche’s Giredestrant Significantly Improved Progression-free Survival in ER-positive Advanced Breast Cancer. Press Release. September 21, 2025.
  3. Eli Lilly and Company. U.S. FDA Approves Inluriyo (Imlunestrant) for Adults with ER+, HER2-, ESR1-mutated Advanced or Metastatic Breast Cancer. Press Release. Sept 25, 2025.
  4. FDA. FDA Approves Pembrolizumab and Berahyaluronidase Alfa-pmph for Subcutaneous Injection. FDA Announcement. Sept 19, 2025.
  5. Pfizer. Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio. Press Release. Sept 22, 2025.

Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.